Anti-cancer Humanized Monoclonal Antibody Agtuzumab Mammalian Cell Expression Platform And Its Application

Cancer is threatening the health of human kind.AGR2 is a protein disulfide isomerase,which is over-expressed in multiple kinds of tumor cells and closely related to cancer proliferation,metastasis and chemoresistance.Thus,AGR2 is a potential anti-cancer target.The monoclonal antibody against AGR2 has the advantages of high specificity and low side-effects.However,murine monoclonal antibody against AGR2 suffers from its immunogenicity.The humanized monoclonal antibody,Agtuzumab,solves such a problem,which is hopeful to become a novel anti-cancer candidate.On the way of Agtuzumab to be a drug,solving the problem of producing Agtuzumab in large-scale is a must.Hence,high-productive and stable antibody expression platform is needed.The aim of this research is to construct the anti-cancer humanized monoclonal antibody Agtuzumab mammalian cell expression platform,which can finally promote the pre-clinical study of Agtuzumab.Here,we reported the results in construction of the platform.We used a fluorescence-based cell line screening system with removable selection marker,which can be removed by Cre/Lox P system.What’s more,we banked the high-productive and stable cell lines.Finally,we expressed,purified Agtuzumab with affinity column and tested its apparent affinity and anti-cancer efficacy.To sum up,these results can promote the pre-clinical and industrial research of Agtuzumab.